

XP-002079561

1/1 - (C) WPI / DERWENT
AN - 95-242756 q32!
AP - JP920281017 920924
PR - JP920281017 920924
TI - Human parvovirus gene coding for a polypeptide - useful
for developing vaccines against parvoviral diseases
such as erythroblastemia, haemorrhagic fever, etc.
IW - HUMAN PARVOVIRUS GENE CODE POLYPEPTIDE USEFUL DEVELOP
VACCINE DISEASE HAEMORRHAGE FEVER
PA - (DENK-N) DENKA SEIKEN KK
- (ELED) DENKI KAGAKU KOGYO KK
PN - JP7147986 A 950613 DW9532 C12N15/09 038pp
ORD - 1995-06-13
IC - C07K14/015 ; C12N1/21 ; C12N5/10 ; C12N15/09 ;
C12P21/02 ; C12Q1/68 ; C12Q1/70 ; G01N33/53 ; G01N33/569
FS - CPI;EPI
DC - B04 D16 S03
AB - J07147986 Human parvovirus gene composed of 4680 bases
(sequence given in the specification) and coding for a
polypeptide is new. Also claimed are human parvovirus
structural genes VP-1 and VP-2 encoding 781 and 554
amino acid sequences, respectively, and non-structural
(NS) gene encoding the 660 amino acid sequence (all
given in the specification).
- USE - The genes are useful for diagnosis and
development of vaccines for parvoviral diseases
including erythroblastemia, abortion, universal foetal
hydrops, liver diseases, haemorrhagic fever, arthritis
and rheumatism.
- ADVANTAGE - The coding sequences make possible mass
prodn. of parvovirus antigen with high yield.
- (Dwg.0/17)